Evotec Se Adr Stock Today
| EVO Stock | USD 4.72 0.03 0.64% |
Performance10 of 100
| Odds Of DistressLess than 27
|
Evotec SE is selling at 4.72 as of the 3rd of December 2024; that is 0.64% increase since the beginning of the trading day. The stock's open price was 4.69. Evotec SE has about a 27 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat ok performance during the last 90 days. Equity ratings for Evotec SE ADR are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of October 2024 and ending today, the 3rd of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of December 2009 | Category Healthcare | Classification Health Care |
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. Evotec Se operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 355.11 M outstanding shares of which 449.7 K shares are currently shorted by investors with about 2.32 days to cover. More on Evotec SE ADR
Moving together with Evotec Stock
Moving against Evotec Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Evotec Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Member CEO | Mario DPHIL | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, OMX Stockholm, OMX Stockholm Large, OMX Nordic 40, OMX Stockholm GI, OMXS 30 Index, OMX Stockholm 30, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEvotec SE can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Evotec SE's financial leverage. It provides some insight into what part of Evotec SE's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evotec SE ADR (EVO) is traded on NASDAQ Exchange in USA. It is located in Essener Bogen 7, Hamburg, Germany, 22419 and employs 5,007 people. Evotec SE is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 1.7 B. Evotec SE ADR runs under Biotechnology sector within Health Care industry. The entity has 355.11 M outstanding shares of which 449.7 K shares are currently shorted by investors with about 2.32 days to cover.
Evotec SE ADR has about 823.67 M in cash with 33.95 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.33.
Check Evotec SE Probability Of Bankruptcy
Ownership AllocationEvotec SE holds a total of 355.11 Million outstanding shares. Roughly 97.81 percent of Evotec SE outstanding shares are held by general public with 2.19 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Evotec Ownership Details
Evotec Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Quadrant Capital Group Llc | 2024-09-30 | 6.2 K | |
| Bank Of America Corp | 2024-06-30 | 6 K | |
| Signaturefd, Llc | 2024-09-30 | 5.2 K | |
| Briaud Financial Planning Inc | 2024-09-30 | 2.2 K | |
| U.s. Bancorp | 2024-06-30 | 1.7 K | |
| Ubs Group Ag | 2024-09-30 | 1 K | |
| Lindbrook Capital, Llc | 2024-09-30 | 712 | |
| Accent Capital Management Llc | 2024-09-30 | 412 | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 332 | |
| Novo A/s | 2024-06-30 | 14.8 M | |
| Mubadala Investment Company Pjsc | 2024-09-30 | 4.6 M |
Evotec SE Historical Income Statement
Evotec Stock Against Markets
Evotec SE Corporate Management
| Christiane Honisch | SVP Diagnostics | Profile | |
| Matthias Evers | Chief Board | Profile | |
| Monika Conradt | Global Resources | Profile | |
| MBA MPA | Member Board | Profile | |
| Christian Dargel | EVP Compliance | Profile | |
| Anja Bosler | Principal Accounting | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evotec SE. If investors know Evotec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evotec SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 2.1925 | Quarterly Revenue Growth (0.06) | Return On Assets (0.02) | Return On Equity (0.16) |
The market value of Evotec SE ADR is measured differently than its book value, which is the value of Evotec that is recorded on the company's balance sheet. Investors also form their own opinion of Evotec SE's value that differs from its market value or its book value, called intrinsic value, which is Evotec SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evotec SE's market value can be influenced by many factors that don't directly affect Evotec SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evotec SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evotec SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evotec SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.